Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Ambrisentan and Tadalafil Fixed Dose Combinations
NCT02688387Phase 1Completed
- Sponsor
- GSK
- Start
- Mar 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ambrisentan and tadalafil in pulmonary arterial hypertension (PAH) (3 arms), sponsored by GSK. Primary endpoints: Maximum Observed Concentration, Area Under the Plasma Concentration Time Curve From Time Zero to Infinite Time and 1 more. Started Mar 2016; status: completed.
02
Drugs
ambrisentantadalafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02688387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02688387.